New Genetically Engineered Mouse Provides Better Model of Alzheimer's Disease

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


By crossing two strains of mice that are now used to study Alzheimer's, researchers from the Mayo Clinic in Jacksonville, Fla., have created an even better animal model of the disease. The new mice succumb to all the symptoms of their parents. From one side, they inherit a mutation in the gene encoding the amyloid precursor protein (APP) and as a result develop amyloid plaques. From the other parent, they bear mutations in the tau-protein gene and thus exhibit tau-related neurofibrillary tangles. And as such, these animals¿a strain christened TAPP for tau and APP¿are the first to develop both of the hallmark brain lesions seen in human Alzheimer's disease.

The researchers hope the TAPP mice will shed light on the development of Alzheimer's and, specifically, whether the plaques lead to the tangles or vice versa. "What we saw in the crossbred mice were not only plaques and tangles, but the tangle pathology was enhanced in regions where the plaques occurred," Mayo scientist Michael Hutton explains. "If we were simply seeing random changes in the tangle pathology in areas that weren't related to amyloid or Alzheimer's disease, this would not be so interesting. The key point is we see the enhanced tangle pathology in areas that are affected in Alzheimer's."

For the moment, the scientists have started testing the amyloid vaccine, announced this past December, on the TAPP animals and hope to refine the mouse model even further. "One of the biggest problems we have is that the tau mice don't live all that long," Hutton says. "They start to die at an age when the pathology in the amyloid mice hasn't reached its final stage." To solve the problem, the team is trying to engineer mice that deposit amyloid plaques more quickly. "This will basically let us compress the time frame of these studies," Hutton adds, "allowing us to look at mice that have lots of amyloid together with tau pathology, and to do it all within the life span of these crossed animals."

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe